Ixazomib
- Generic Name
- Ixazomib
- Brand Names
- Ninlaro
- Drug Type
- Small Molecule
- Chemical Formula
- C14H19BCl2N2O4
- CAS Number
- 1072833-77-2
- Unique Ingredient Identifier
- 71050168A2
- Background
Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple...
- Indication
Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
- Associated Conditions
- Multiple Myeloma (MM)
- Associated Therapies
- -
Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2018-11-08
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT01645930
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2012-03-28
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- Takeda
- Target Recruit Count
- 722
- Registration Number
- NCT01564537
- Locations
- 🇺🇸
University of Arkansas Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Pacific Cancer Medical Center Inc, Anaheim, California, United States
🇺🇸West Contra Costa Healthcare District, Berkeley, California, United States
Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2011-06-28
- Last Posted Date
- 2019-03-21
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT01383928
- Locations
- 🇺🇸
Virginia Cancer Specialists PC, Fairfax, Virginia, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2011-04-14
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT01335685
Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis
- First Posted Date
- 2011-03-21
- Last Posted Date
- 2020-04-01
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT01318902
- Locations
- 🇩🇪
Universitatsklinikum Heidelberg Innere Medizin V; Hamatologie, Onkologie und Rheumatologie, Heidelberg, Germany
🇺🇸Mount Sinai Medical Center, New York, New York, United States
🇮🇹Amyloidosis Research & Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2010-10-08
- Last Posted Date
- 2018-03-14
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT01217957
- Locations
- 🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸Mt Sinai Medical Center, Miami Beach, Florida, United States
🇺🇸Mayo Clinic Arizona, Scottsdale, Arizona, United States
Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma
- First Posted Date
- 2009-07-03
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00932698
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study of IXAZOMIB in Adult Patients With Lymphoma
- First Posted Date
- 2009-05-06
- Last Posted Date
- 2015-11-11
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT00893464
- Locations
- 🇺🇸
Tower Cancer Research Center, Beverly Hills, California, United States
🇺🇸University of Wisconsin Madison, Madison, Wisconsin, United States
🇨🇦Jewish General Hospital, Montreal, Quebec, Canada
A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies
- First Posted Date
- 2009-01-28
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT00830869
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸University of Washington- Seattle Cancer Care, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.